Eptifibatide

Eptifibatide is a cyclic heptapeptide designed to inhibit platelet aggregation by blocking the glycoprotein IIb/IIIa (GP IIb/IIIa, integrin alphaIIb-beta3) receptor. The compound was rationally designed based on the structure of barbourin, a disintegrin peptide from pygmy rattlesnake venom that contains the unusual KGD (Lys-Gly-Asp) sequence rather than the canonical RGD.

GP IIb/IIIa is the most abundant integrin on platelets and the final common pathway for platelet aggregation. Upon platelet activation, conformational changes expose the receptor's fibrinogen binding site, enabling platelet crosslinking. By mimicking the KGD/RGD sequence recognized by GP IIb/IIIa, eptifibatide competitively blocks fibrinogen binding and prevents platelet aggregation.

The disulfide-cyclized structure constrains the KGD motif in an optimal conformation for receptor binding while providing metabolic stability. The homoarginine residue (one carbon longer than lysine) optimizes receptor affinity. This design exemplifies successful development of peptide therapeutics from venomous animal toxins.

Clinically, eptifibatide is used in acute coronary syndromes and during percutaneous coronary intervention to prevent thrombotic complications. Its short half-life (approximately 2.5 hours) allows rapid offset of antiplatelet effect, advantageous if bleeding complications occur or urgent surgery is needed.